Cell News and Research

RSS

Research suggests a potential means of circumventing drug resistance in breast cancer patients

Overexpression of low-molecular-weight (LMW-E) forms of the protein cyclin E renders the aromatase inhibitor letrozole ineffective among women with estrogen-receptor-positive (ER+) breast cancers, researchers from The University of Texas M. D. Anderson Cancer Center report in Clinical Cancer Research.

10 Feb 2010

Study: New mechanism may allow bacteria to develop resistance to antibiotics

Scientists have shown that cells' DNA-reading machinery can skim through certain kinds of damaged DNA without skipping any letters in the genetic "text." The studies, performed in bacteria, suggest a new mechanism that can allow bacteria to develop resistance to antibiotics.

10 Feb 2010

Ikonisys to showcase oncoFISH cervical test at Eurogin 2010 Cervical Cancer Prevention Conference

Ikonisys announced today that they will exhibit their proprietary oncoFISH® cervical test at the Eurogin 2010 Cervical Cancer Prevention Conference held at the Grimaldi Forum in Monte Carlo from February 17-20.

10 Feb 2010

Study could lead to new therapeutic strategies for Parkinson's disease

A new study from The Montreal Neurological Institute and Hospital - The Neuro - at McGill University is the first to discover a molecular link between Parkinson's disease and defects in the ability of nerve cells to communicate.

10 Feb 2010

IgM/IgG ratio is useful in diagnosing primary biliary cirrhosis

Previous studies have shown that assessment of immunoglobulin subclasses in plasma cells by immunohistochemistry (IHC) may be useful in the histopathologic evaluation of autoimmune liver diseases. However, further studies are necessary in order to validate the diagnostic utility of IgM and IgG immunohistochemistry in this specific scenario.

10 Feb 2010

Advaxi to receive fund from CRUK for clinical trial of ADXS11-001

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, is pleased to announce that Cancer Research UK (CRUK), the UK philanthropy dedicated to cancer research, has agreed to fund the cost of a clinical trial to investigate the use of ADXS11-001, Advaxis’ lead human papilloma virus (HPV)-directed vaccine candidate, for the treatment of head and neck cancer.

10 Feb 2010

Whooping cough vaccine may be losing its punch: study

Vaccination programs against whooping cough may not be fully effective because the bacteria that cause the disease have evolved new strains, a new study has found.

9 Feb 2010

Physical Activity Innovations named ‘Bluetooth Innovator of the Year’ for 2009

The Bluetooth SIG has awarded Edward Sazonov, Physical Activity Innovations LLC, the title of Bluetooth Innovator of the Year for 2009. Sazonov received this recognition at the official award ceremony held in-line with the Wearable Technologies Show at ispo 2010, the world’s largest trade show for sporting goods.

9 Feb 2010

Gene linked to PMDD and other maladies during menstrual cycle

Scientists have identified a gene they say is a strong candidate for involvement in premenstrual dysphoric disorder (PMDD) and other maladies associated with the natural flux in hormones during the menstrual cycle. In a paper to be published today in the Proceedings of the National Academy of Sciences, Rockefeller University researchers detail experiments in mice showing that a common human variant of the gene increases anxiety, dampens curiosity and tweaks the effects of estrogen on the brain, impairing memory.

9 Feb 2010

Preliminary study results of ExThera Medical's Seraph extracorporeal affinity therapy published

ExThera Medical announced today that the results of a preliminary study (“Cytokines in blood from septic patients interact with surface immobilized heparin”) of its proprietary medical device, Seraph™ extracorporeal affinity therapy, have been published in the current issue of the Journal of the American Society for Artificial Organs (Jan.-Feb. 2010).

9 Feb 2010

NNK induces epigenetic alteration during cancer formation and inhibits tumor suppressor genes

In the history of humans fighting against cancer, the relationship between tobaccos and cancer has been an important subject for the academic and clinical research. By understanding the mechanism of why cancer is caused by tobaccos, scientists around the world all anticipate to solve the mystery of cancer and find the way of prevention and cure.

9 Feb 2010

Thymosin β4 exhibits potential as new therapeutic agent for liver failure due to chronic HBV infection

REGENERX BIOPHARMACEUTICALS, INC. announced today that researchers have correlated Tβ4 levels with the clinical course of patients with hepatitis B virus-related liver failure. It was reported that serum thymosin β4 levels were significantly lower in patients with chronic hepatitis B infection and that the magnitude of the reduction of thymosin β4 was closely related to the severity of the hepatic injury and to patient death. Since patients with higher Tβ4 levels survived the disease, changes in Tβ4 values could reflect outcome in some liver failure patients.

9 Feb 2010

Researchers explore cellular networks that regulate cell morphology

Cellular imaging offers a wealth of data about how cells respond to stimuli, but harnessing this technique to study biological systems is a daunting challenge.

9 Feb 2010

Italian researchers identify a new therapeutic approach for Ewing sarcoma

Ewing sarcoma (EWS) is a bone tumor of unknown cellular origin that affects children and young adults. The protein CD99 is highly expressed in most cases of EWS, but its function in the disease is unknown.

9 Feb 2010

Synta Pharmaceuticals' STA-9090 inhibits WT1 protein in AML

Synta Pharmaceuticals Corp. today announced that preclinical results presented at the “Bridging the Gap 2010” Hematologic Conference, held in Singapore City, Singapore, February 5-7, 2010, shows that STA-9090, a potent inhibitor of heat shock protein 90 (Hsp90), inhibits the Wilms’ tumor 1 (WT1) protein, a key transcription factor that drives disease progression in acute myeloid leukemia (AML) as well as certain other leukemias. STA-9090 is currently enrolling patients in two clinical trials in AML and other hematologic cancers.

9 Feb 2010

Findings point towards new therapeutic approach for breast and prostate cancer

In a new approach to developing treatments for breast cancer, prostate cancer and enlarged hearts, Loyola University Stritch School of Medicine researchers are zeroing in on a workhorse protein called RSK.

9 Feb 2010

Cell Therapeutics' pixantrone NDA: FDA postpones ODAC meeting due to severe weather conditions

Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that the United States Food and Drug Administration informed CTI that due to severe weather conditions in the Washington, D.C. area, the FDA is postponing the Oncologic Drugs Advisory Committee ("ODAC") meeting that was to be held on Wednesday, February 10, 2010 to discuss the pixantrone New Drug Application ("NDA"). The FDA indicated that it intends to reschedule the meeting as soon as the FDA can determine a schedule that will allow them to reconvene the advisory panel.

9 Feb 2010

Texting-on-the-go can cause fatal accidents

Siobhan Wicks was texting her roommate while walking down the stairs in her Aurora home when suddenly her world turned topsy turvy.

9 Feb 2010

U.S. Court dismisses two of ADI's patent infringement claims against Knowles Electronics

The U.S. District Court in the District of Delaware has ordered the dismissal of two patent infringement claims originally filed by Analog Devices, Inc. (ADI) against Knowles Electronics. The order was issued pursuant to the withdrawal of its claims by Analog Devices under a stipulation of dismissal signed by both parties.

9 Feb 2010

Denosumab exhibits superiority over Zometa in treatment of prostate cancer men with bone metastases

Amgen today announced that a pivotal, Phase 3, head-to-head trial evaluating denosumab versus Zometa® (zoledronic acid) in the treatment of bone metastases in 1,901 men with advanced prostate cancer met its primary and secondary endpoints.

9 Feb 2010

Cell News and Research

Research suggests a potential means of circumventing drug resistance in breast cancer patients

Study: New mechanism may allow bacteria to develop resistance to antibiotics

Ikonisys to showcase oncoFISH cervical test at Eurogin 2010 Cervical Cancer Prevention Conference

Study could lead to new therapeutic strategies for Parkinson's disease

IgM/IgG ratio is useful in diagnosing primary biliary cirrhosis

Advaxi to receive fund from CRUK for clinical trial of ADXS11-001

Whooping cough vaccine may be losing its punch: study

Physical Activity Innovations named ‘Bluetooth Innovator of the Year’ for 2009

Gene linked to PMDD and other maladies during menstrual cycle

Preliminary study results of ExThera Medical's Seraph extracorporeal affinity therapy published

NNK induces epigenetic alteration during cancer formation and inhibits tumor suppressor genes

Thymosin β4 exhibits potential as new therapeutic agent for liver failure due to chronic HBV infection

Researchers explore cellular networks that regulate cell morphology

Italian researchers identify a new therapeutic approach for Ewing sarcoma

Synta Pharmaceuticals' STA-9090 inhibits WT1 protein in AML

Findings point towards new therapeutic approach for breast and prostate cancer

Cell Therapeutics' pixantrone NDA: FDA postpones ODAC meeting due to severe weather conditions

Texting-on-the-go can cause fatal accidents

U.S. Court dismisses two of ADI's patent infringement claims against Knowles Electronics

Denosumab exhibits superiority over Zometa in treatment of prostate cancer men with bone metastases

What are the challenges of cell line development? eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo